Kayentis and RWS Partner to Boost Data Trust in CNS Clinical Trials

Meylan, France and Maidenhead, UK – April 15, 2026 – In a significant move to address one of the most persistent challenges in drug development, eCOA leader Kayentis and AI solutions company RWS have announced a strategic partnership. The collaboration integrates RWS’s specialized rater training services directly into Kayentis's electronic Clinical Outcome Assessment (eCOA) platform, creating a unified solution designed to enhance data confidence and reliability in complex clinical trials, particularly within the challenging field of Central Nervous System (CNS) research.

This joint effort aims to tackle the pervasive issue of variability in how clinicians score patient outcomes, a problem that can undermine the validity of trial results and delay the development of new therapies for neurological and psychiatric disorders.

The High Cost of Inconsistency

The field of neuroscience is a high-stakes arena for pharmaceutical development, characterized by immense patient need but plagued by staggering failure rates. CNS drugs have a success rate of just 6.2%, less than half that of non-CNS compounds. Development timelines are also significantly longer, averaging over a year more than other therapeutic areas. A primary contributor to these grim statistics is the challenge of collecting clean, reliable data.

CNS trials often rely on Clinician-Reported Outcomes (ClinROs), where a trained clinician assesses a patient's condition using complex rating scales. These assessments are inherently subjective and highly susceptible to what is known as “rater drift”—subtle inconsistencies in how different clinicians, or even the same clinician over time, administer tests and score results. Research indicates this variability can erode data integrity by as much as 72%, introducing noise that obscures a potential treatment's true effect. The consequences are severe: compromised trial validity, inflated costs from the need for larger patient cohorts, and critical delays in decision-making.

“Capturing data digitally isn’t enough, sponsors need data they can trust,” said Guillaume Juge, CEO at Kayentis, in the announcement. “By aligning rater qualification with purpose-built eCOA workflows, we help reduce variability and give teams greater confidence in their results.”

An Integrated Solution for a Fragmented Problem

Historically, trial sponsors have managed data collection and rater training as separate workstreams, often contracting with different vendors for eCOA technology and clinician training services. The Kayentis-RWS partnership seeks to dismantle this fragmented model by creating a single, quality-driven workflow.

The new integrated solution embeds RWS’s rater training, certification, and ongoing monitoring programs directly within Kayentis’s Clin’form eCOA platform. A pivotal feature of this integration is the implementation of advanced access controls. This technology ensures that only clinicians who are currently certified and qualified for a specific assessment scale can access and enter data for that assessment. This provides a robust, automated safeguard against the use of unqualified or out-of-date raters, a critical risk in long-duration global trials.

By unifying these processes, the partnership aims to deliver a more streamlined operational model for pharmaceutical sponsors and contract research organizations (CROs). This not only reduces the administrative burden of managing multiple vendors but also creates a cohesive ecosystem where human expertise and technology work in concert to protect the integrity of the data from study start to closeout.

Strategic Moves and a New Market Standard

The announcement formalizes what the companies describe as a long-standing collaboration, built upon recent and significant strategic investments from both sides. This synergy signals a mature understanding of the market's needs and a proactive approach to solving them.

In February 2026, RWS launched its dedicated CNS rater training service, a comprehensive offering designed to tackle data inconsistency in complex global trials. It includes customized training, digital certification, and ongoing monitoring to reduce rater drift over the life of a study. On the other side of the partnership, Kayentis has been steadily enhancing its Clin'form platform and, in January 2025, established a scientific advisory board with deep neuroscience expertise to guide its eCOA strategies.

“Our CNS rater training service was built to tackle one of the biggest risks in neuroscience trials: inconsistent clinician assessments,” commented Dan Herron, global vice president, digital health at RWS. “Working with Kayentis allows us to connect that expertise directly to how data is captured in real-world trial environments.”

This deliberate convergence of specialized training and advanced technology could set a new standard for data quality in the industry, potentially compelling competitors to develop similarly integrated offerings to remain competitive.

From Data Quality to Patient Impact

Beyond the operational efficiencies and strategic market positioning, the ultimate significance of this partnership lies in its potential impact on patients. By strengthening endpoint reliability, the integrated solution can help researchers detect a drug's true signal more clearly and confidently. This improved data quality could lead to more efficient trials that require fewer participants and reach conclusions faster.

This approach also aligns with tightening regulatory expectations from bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), both of which have issued guidance emphasizing the importance of data integrity, traceability, and the use of validated electronic systems in clinical trials. The Kayentis-RWS solution, with its auditable certification tracking and controlled data entry, is well-positioned to meet these stringent standards.

For the millions of patients awaiting breakthroughs for conditions like Alzheimer's disease, Parkinson's disease, and major depressive disorder, the a more reliable clinical trial process can accelerate the journey of life-changing therapies from the lab to the clinic. The joint solution from Kayentis and RWS is available immediately for sponsors and CROs, offering a ready-to-deploy tool in the critical fight against neurological disease.